Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 USD | -2.96% | -1.67% | -28.74% |
Jun. 05 | Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target | MT |
May. 08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.74% | 89.01M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.25% | 22.78B | |
-11.07% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor